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Abstract Both acute myeloid leukemia 1 and c-Fos are
regulatory factors of hematopoietic cell differentiation. We
identified that the c-fos promoter contains an acute myeloid
leukemia 1 binding site at nucleotide positions 36^+14. c-fos
promoter activity was induced by transient overexpression of
acute myeloid leukemia 1 in Jurkat T-cells, but not by that of the
short form of acute myeloid leukemia 1-MTG8, a chimeric acute
myeloid leukemia 1 protein. In 32Dcl3 myeloid cells, stable
overexpression of acute myeloid leukemia 1-MTG8 blocked the
c-fos gene transcription and cell differentiation, but that of acute
myeloid leukemia did not. These data suggest that acute myeloid
leukemia 1 and acute myeloid leukemia 1-MTG8 reciprocally
regulate the myeloid cell differentiation, possibly by the way of
regulating c-fos gene transcription.
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1. Introduction
The process by which multiple types of terminally di¡er-
entiated blood cells are produced from a common pluripotent
hematopoietic stem cell is controlled in part by transcription
factors that regulate the expression of lineage-speci¢c genes
[1,2]. One transcription factor that plays a central role in
hematopoiesis is the polyomavirus enhancer binding protein
2 (PEBP2), also known as core binding factor (CBF). PEBP2/
CBF is composed of K and L subunits [3]. The K subunit
shares sequence similarity with the Drosophila segmentation
gene runt [4]. The Runt domain of PEBP2K harbors both the
DNA binding and dimerization activities [5,6]. The L subunit
of PEBP2/CBF, PEBP2L, interacts directly with the K subunit
and increases its DNA binding a⁄nity [6,7]. This e¡ect on
DNA binding is essential for PEBP2K to function in vivo [8].
Three mammalian genes, termed PEBP2KA [9], PEBP2KB
[10] and PEBP2KC [11] have been shown to encode the K sub-
unit of PEBP2/CBF. It has been suggested that PEBP2KB, also
known as acute myeloid leukemia 1 (AML1), is an important
factor in the regulation of hematopoietic cell di¡erentiation
[12]. Disruption of the AML1 gene in mice yields a pheno-
type: impaired hematopoiesis of all cell lineages in the fetal
liver [12,13]. AML1 was originally identi¢ed at the breakpoint
of the 8 to 21 chromosome translocation t(8;21) [14], which
encodes the fusion protein AML1-MTG8 and is associated
with human acute myeloid leukemia [15,16]. Two alternate
AML1-MTG8 transcripts, the short and long forms, arise as
a consequence of alternative splicing events. Only the long
form contains two putative zinc ¢nger domains and proline-
rich regions in the C-terminal part of the protein [17]. Over-
expression of the long form of AML1-MTG8 in myeloid pro-
genitor cells prevents granulocyte colony stimulating factor
(G-CSF)-induced di¡erentiation [18,19]. However, the func-
tion of the short form is not yet known.
Although AML1 and AML1-MTG8 are known to play a
key role in hematopoietic cell development, the target genes
regulated by AML1 or AML1-MTG8 are not much known.
The consensus DNA sequence recognized by the Runt domain
of AML1 or AML1-MTG8, (Pu/T)ACCPuCA [3,5] is present
in the enhancers and promoters of several mammalian genes,
including the T-cell receptor genes [20], the myeloperoxidase
gene [21], granulocyte macrophage colony stimulating factor
[22] and the interleukin-3 gene [23]. Abnormal expressions of
these genes are thought to be associated with leukemogenesis.
c-Fos, a component of the AP-1 transcription factor com-
plex is also widely recognized as a key regulator involved in
the development of bones, teeth and hematopoietic cells [24^
27]. The c-fos mRNA levels were shown to be elevated during
myeloid cell di¡erentiation and in terminally di¡erentiated
myeloid cells [28]. c-fos gene transcription is modulated by
several regulatory gene elements, including the serum response
element (SRE) [29], sis inducible element (SIE) [30], AP1/
cAMP response element [31] and others [32]. Although the
c-fos promoter has been studied extensively, there are still a
number of issues that remain unresolved with respect to its
regulation.
Since both Runt proteins and c-Fos are playing essential
roles in the development of hematopoietic cells, we examined,
in this study, whether these proteins are functionally associ-
ated in the regulation of hematopoietic cell di¡erentiation.
2. Materials and methods
2.1. Cell culture
A Jurkat human T-cell leukemia cell line (ATCC TIB-152) was
grown in RPMI 1640 medium (Gibco BRL) supplemented with 10%
fetal bovine serum (FBS, Gibco BRL) and penicillin-streptomycin
(Gibco BRL). A murine IL-3-dependent myeloid progenitor cell line
(32Dcl3) derived from a normal bone marrow long term culture [33]
was maintained in Iscove’s modi¢ed Dulbecco’s medium (IMDM,
Gibco BRL) supplemented with 10% FBS and 0.25 ng/ml of IL-3
(Sigma) and cultured in the presence of 5 ng/ml of recombinant hu-
man G-CSF (Sigma) for the induction of granulocytic di¡erentiation.
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Viable cells excluding trypan blue were counted with a hemocytom-
eter.
2.2. Transient transfection and luciferase assays
Jurkat T-cells (2U106 cells) were transfected with 0.25 Wg of report-
er plasmid and 0.25^2 Wg of each expression vector per sample using
LipofecTAMINE reagent (Gibco BRL) as instructed by the manufac-
turer. The luciferase reporter plasmid has the full length promoter
region (3711^+45) of the human c-fos gene (pFos-lcf). pCMVL-gal
was included as an internal control for the transfection e⁄ciency.
Luciferase activity was measured with an AutoLumat LB953 lumin-
ometer (Berthold) using a Promega luciferase assay system kit.
2.3. Gene construction and establishment of stable cell lines
AML1 and AML1-MTG8 (short form) expression vectors were
constructed by the insertion of each cDNA into a 6UHis-tagged
pRc-CMV vector (Invitrogen). After transfection of the AML1 and
AML1-MTG8 expression vectors into 32Dcl3 cells, we selected stable
transformants on incubating the transfected cells in the presence of
G418 (800 Wg/ml) for 2 weeks and performing limiting dilutions to
obtain clonal isolates.
2.4. Electrophoretic mobility shift assay (EMSA)
Protein-DNA binding reactions were performed as described previ-
ously [22]. The DNA probe was labelled with Q-[32P]ATP (Amersham)
in a standard T4 polynucleotide kinase (Boehringer, Mannheim) re-
action. For supershift and competition assays, the proteins were pre-
incubated with PEBP2K, PEBP2L or competitors and then mixed with
DNA probe
2.5. Northern blot analysis
Total RNA was isolated from cultured cells using the RNeasy mini
kit (QIAGEN), separated on a 1% agarose-formaldehyde gel and
transferred onto a nylon membrane (Hybond N+, Amersham). For
Northern blotting, the MPO and L-actin cDNA probes were gener-
ated by RT-PCR and the rat c-Fos cDNA template was obtained by
BglII-XhoI digestion of the pFos (SP65) plasmid [34]. The various
probes were labelled with K-[32P]dCTP (Amersham) using the redi-
prime system (Amersham). The membrane with cross-linked RNA
was hybridized with denatured DNA probes.
3. Results
3.1. Identi¢cation of AML1 binding site within the c-fos
promoter
The computer-aided nucleotide sequence analysis suggested
that the c-fos gene promoter contains a putative AML1 bind-
ing sequence. Thus, we tested whether the c-fos gene is a
target gene for AML1. We screened upstream sequences of
the c-fos gene for the consensus AML1 binding sequence. The
upstream regions of the c-fos gene contain four putative
AML1 binding related sites, denoted as P1 (3493^3476),
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Fig. 1. (a) Schematic representation of the proximal region of the c-
fos promoter and the probe sequences used in EMSA. The tran-
scription initiation site is indicated by +1 and the transcriptional
regulatory sites are indicated above the rectangle by SIE, SRE,
AP1/CRE and TATA. The AML1 binding consensus motif is
underlined in P1, P2, P3 and P4. The mP3 indicates the mutated P3
site (ACT and CCG). (b) DNA binding assays of puri¢ed Runt
protein. Each probe was indicated at the bottom of the panels. Pu-
ri¢ed PEBP2L protein was added to the reaction mixture to give
rise to an additional shifted complex. The absence (3) or presence
(+) of Runt and PEBP2L is indicated above each panel.
Fig. 2. Supershift and competition assays. (a) Puri¢ed Runt protein was mixed with 32P-labelled P3 probe in the absence (lane 2) and presence
of increasing amounts (5, 10 or 50 molar excess) of competitors (lanes 3^5, P3; lanes 6^8, vF9-5000; lanes 9^11, mP3) and incubated at 30‡C
for 15 min. The reaction products were analyzed by electrophoresis on a 6% non-denaturing polyacrylamide gel. (b) Jurkat T-cell nuclear ex-
tracts were pre-incubated with pre-immune (lane 2), PEBP2K (lane 3) or PEBP2L (lane 4) speci¢c antibody. PI means preimmune serum and
* denotes the supershifted band. (c) Jurkat T-cell nuclear extracts were mixed with P3 probe in the presence of competitors (lanes 2^4, P3;
lanes 5^7, vF9-5000; lanes 8^10, mP3) or in the absence of a competitor (lane 11). Lane 1 (a^c) is the no protein control lane.
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P2 (3223^3205), P3 (36^+14) and P4 (+65^+83) (Fig. 1a).
Using DNA probes with the nucleotide sequences of these
four putative sites, we performed EMSA with puri¢ed Runt
protein, which is the DNA binding moiety of AML1. Among
the sites tested, P3 was the only site that displayed sequence-
speci¢c Runt binding activity (Fig. 1b). The protein binding
a⁄nity of P3 was comparable with that of vF9-5000, a high
a⁄nity AML1 binding oligonucleotide [3] (Fig. 1b). In addi-
tion, the mobility of both DNA-protein complexes was shifted
by the addition of puri¢ed PEBP2L protein, as shown previ-
ously [6,9]. These data clearly suggest that Runt protein binds
directly to the P3 site within the c-fos promoter.
3.2. AML1 and AML1-MTG8 bind in a sequence-speci¢c
manner to the P3 site within the c-fos promoter.
To determine whether Runt binds in a sequence-speci¢c
manner to the P3 site, we performed competition assays using
the following oligonucleotide competitors: wild-type P3, vF9-
5000 and a mutated form of P3 (mP3), in that the A and C
residues known as important nucleotides for Runt protein
binding, were mutated to T and G, respectively. Addition of
excessive unlabelled P3 or vF9-5000 competitor to the DNA
binding reaction inhibited completely the formation of the P3-
Runt complex, whereas the mP3 competitor did not a¡ect the
complex formation (Fig. 2a). These data suggest that Runt
protein binds to the P3 site in a sequence-speci¢c manner.
Thus, we examined whether the native Runt protein can
also bind speci¢cally to the P3 site. Cockerill and colleagues
[22] showed that the PEBP2K/L complex in the nuclear frac-
tion of Jurkat T-cells binds speci¢cally to the AML1 gene
regulatory element using a supershift assay. Our data showed
that the protein-DNA complex was shifted by the addition of
PEBP2K or L antibody (Fig. 2b). The result also showed that
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Fig. 3. The e¡ect of AML1 and AML1-MTG8 on the c-fos pro-
moter activity. Jurkat T-cells were co-transfected with the wt c-fos
or mt c-fos luciferase reporter gene and increasing amounts of
AML1 (a) or AML1-MTG8 (b) expression vector. (c) In a separate
experiment, Jurkat T-cells were co-transfected with a wt c-fos luci-
ferase reporter gene and AML1-MTG8 expression vector, without
(3AML1) or with (+AML1) the AML1 expression vector. Lucifer-
ase activities were normalized to the L-galactosidase activity of each
protein extract. Each value represents the mean of four independent
experiments. Standard deviations are indicated by error bars.
Fig. 4. (a) Schematic structure of AML1 (451 aa) and the short
form of AML1-MTG8 (395 aa). (b) Immunoblotting of AML1 and
AML1-MTG8. A1 and A2 indicate selected AML1-32Dcl3 clones.
M1 and M2 indicate AML1-MTG8-32Dcl3 clones. (c) Growth
curves in AML1-32Dcl3 and AML1-MTG8-32Dcl3 cells in response
to G-CSF. At each time point (days), viable cells excluding trypan
blue were counted using a hemocytometer. Three independent ex-
periments were performed. (d) Northern blot analysis. Total RNA
was prepared from AML1-32Dcl3 and AML1-MTG8-32Dcl3 at 0,
1, 3 or 5 days after treatment with G-CSF and analyzed by North-
ern blotting using 32P-labelled MPO cDNA as a probe. The L-actin
mRNA levels were analyzed as an internal control.
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the native K/L complex in Jurkat T-cell extracts bound to the
P3 site, whereas, the complex formation was inhibited com-
petitively by an excess P3 and vF9-5000, but not by mP3 (Fig.
2c). Moreover, the in vitro translated proteins of AML1 and
AML1-MTG8, Runt protein family, bound speci¢cally to the
P3 site (data not shown). Thus, we concluded that the mem-
bers of the Runt protein family, AML1 and AML1-MTG8
can bind to the P3 site in a sequence-speci¢c manner.
3.3. AML1 and AML1-MTG8 reciprocally regulate
transcriptional activity of the c-fos gene through the P3 site
To examine whether the interaction of AML1 or AML1-
MTG8 with the P3 site regulates c-fos promoter activity, we
performed transient transfection assays with the wild- (wt) or
mutant-type (mt) c-fos promoter linked to a luciferase report-
er gene. The mt c-fos reporter gene contains mP3 sequences
replaced in the P3 site. Jurkat T-cells were transfected with a
¢xed amount of the reporter gene and increasing amounts of
an AML1 expression vector. Our results showed that wt c-fos
promoter activity was induced by AML1 overexpression (Fig.
3a), whereas mt c-fos promoter activity was not altered. In-
terestingly, wt c-fos promoter activity was inhibited by over-
expression of AML1-MTG8 (Fig. 3b). Moreover, the wt c-fos
promoter activity induced by AML1 overexpression was also
inhibited by the co-expression of increasing amounts of
AML1-MTG8 (Fig. 3c). These results suggested that AML1
and AML1-MTG8 reciprocally regulate the wt c-fos promoter
through the P3 site and that the inhibitory e¡ect of AML1-
MTG8 can override the inductive e¡ect of AML1 on the c-fos
promoter activity.
3.4. AML1 and AML1-MTG8 reciprocally regulate the
G-CSF-induced myeloid cell di¡erentiation possibly
by a way of regulating c-fos gene transcription
We next examined whether the reciprocal regulation of the
c-fos promoter activity by AML1 and AML1-MTG8 is ac-
cordingly associated with hematopoietic cell di¡erentiation.
To this end, we established the stably transformed 32Dcl3
cell lines, AML1-32Dcl3 and AML1-MTG8-32Dcl3 (Fig.
4a,b). With the AML1-32Dcl3 clones A1 and A2, the number
of viable cells increased until 7 days after G-CSF treatment
and rapidly decreased thereafter. By contrast, with the
AML1-MTG8-32Dcl3 clones M1 and M2, the cells prolifer-
ated continuously after treatment with G-CSF (Fig. 4c).
Moreover, the myeloperoxidase (MPO) mRNA levels, a
marker for myeloid cell di¡erentiation, increased after
G-CSF treatment in AML1-32Dcl3 cells, whereas MPO
mRNA was not detectable in AML1-MTG8-32Dcl3 cells
(Fig. 4d). These data demonstrate that AML1-32Dcl3 cells,
as do 32Dcl3 parental cells, undergo the myeloid cell di¡er-
entiation in response to G-CSF, while in AML1-MTG8-
32Dcl3 cells, the G-CSF-induced cell di¡erentiation is
blocked. In addition, endogenous c-fos gene transcription
was also blocked in AML1-MTG8-32Dcl3 cells treated with
G-CSF. By contrast, c-fos mRNA levels were elevated in pa-
rental and AML1-32Dcl3 cells under the same conditions
(Fig. 5). Thus, it appears that transcriptional regulation of
the c-fos gene by AML1 or AML1-MTG8 is functionally
associated with the myeloid cell di¡erentiation.
4. Discussion
In this article, we described four major observations: (i)
the c-fos promoter harbors an AML1 binding sequence
(36^+14), (ii) the c-fos promoter activity is stimulated by
the overexpression of AML1, but repressed by AML1-
MTG8 overexpression, (iii) AML1-32Dcl3 cells undergo the
myeloid cell di¡erentiation in response to G-CSF, while the
G-CSF-induced cell di¡erentiation is blocked in AML1-
MTG8-32Dcl3 cells and (iv) endogenous c-fos mRNA levels
are repressed in AML1-MTG8-32Dcl3 cells treated with G-
CSF.
There has been ample evidence that AML1 (or AML1-
MTG8) and c-Fos play essential roles in the regulation of
hematopoietic cell development along with most of the mye-
loid lineages [12,24,27]. It has been shown that de¢nitive hem-
atopoiesis becomes defective when the AML1 gene was dis-
rupted in mice. With respect to the role of c-Fos, c-fos mRNA
was shown to be stably expressed in normal myeloid cells
upon the induction of either granulocyte or macrophage dif-
ferentiation by using G-CSF or M-CSF, respectively. The
murine M1 myeloid leukemic cells normally proliferate, but
undergo the terminal di¡erentiation as a consequence of sta-
ble expression of the c-fos gene in the presence of IL-6. In
addition, c-fos antisense oligodeoxynucleotides, but not sense
oligodeoxynucleotides, can block the terminal di¡erentiation
in the cultured cells [28]. Thus, it is evident that c-Fos, as well
as AML1, transcription factors play an important role in the
myeloid cell di¡erentiation. It is unclear, however, whether
these transcription factors regulate coordinately the myeloid
cell di¡erentiation.
Our data reveal that c-fos harbors a novel regulatory gene
element, the AML1 binding site. Earlier reports showed that
the c-fos gene transcription is regulated by several regulatory
elements, among which the SRE plays a major regulatory role
in controlling the c-fos promoter activity [29]. At present, it is
not clear whether the cooperation between AML1 (or AML1-
MTG8) and other transcription factors is important for the
regulation of c-fos gene transcription but the possibility still
exists.
It is also interesting that c-fos promoter activity is recipro-
cally regulated by the overexpression of AML1 and AML1-
MTG8. The C-terminal regions of AML1 and AML1-MTG8
may determine the reciprocal regulation of the c-fos promoter
activity, because the amino acid sequences of AML1 and
AML1-MTG8 di¡er only in this region. The inhibitory e¡ect
of AML1-MTG8 can override the inductive e¡ect of AML1
FEBS 21659 5-3-99
Fig. 5. c-fos mRNA analysis in AML1-32Dcl3 and AML1-MTG8-
32 Dcl3 cell lines. Total RNA was isolated from AML1-32Dcl3 and
AML1-MTG8-32Dcl3 cells treated with G-CSF at the indicated
time points. The RNA-blotted Nylon membrane was hybridized
with a 32P-labelled c-fos cDNA probe. As an internal control, the
L-actin mRNA level was analyzed on the same blot after stripping.
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on the c-fos gene expression. This result is consistent with the
previous report suggesting that AML1-MTG8, a chimeric leu-
kemogenic version of AML1, exerts a dominant e¡ect over
AML1 by competing with AML1 for DNA binding. This
dominant e¡ect has been implicated in the inhibition of ter-
minal di¡erentiation of myeloid lineage cells, which results in
leukemogenesis [35]. Recently, it was reported that AML1
interacts with the transcriptional co-activator, p300 in its C-
terminal region and this results in the induction of myeloid
cell di¡erentiation [36]. By contrast, AML1-MTG8 does not
interact with p300 because the C-terminal region of this chi-
meric protein is replaced by other sequences. Thus, it is very
likely that transcriptional repression of c-fos gene transcrip-
tion by binding of AML1-MTG8 may be related to the failure
of recruiting transcriptional co-activator to the c-fos pro-
moter.
It has also been shown that AML1 (or AML1-MTG8) and
c-Fos are required for the induction of myeloid cell di¡eren-
tiation [19,24]. Consistent with these ¢ndings, our data have
demonstrated that AML1 and AML1-MTG8 reciprocally reg-
ulate the myeloid cell di¡erentiation by the way of regulating
c-fos gene transcription. In this experiment, AML1-32Dcl3, a
stable cell line that overexpresses AML1 in 32Dcl3 cells, was
similar to 32Dcl3 parental cells in views of cell growth pat-
tern, c-fos gene transcription and myeloid cell di¡erentiation
induced by G-CSF. The reason may be explained by that the
endogenous AML1 levels in the parental cells are su⁄cient to
induce c-fos gene transcription and cell di¡erentiation. By
contrast, AML1-MTG8-32Dcl3 cells completely di¡ered
from parental or AML1-32Dcl3 cells. This may be due to
the fact that overexpression of AML1-MTG8 can override
the e¡ect of endogenous AML1 on the c-fos gene transcrip-
tion and cell di¡erentiation. Thus, it appears that AML1 and
AML1-MTG8 reciprocally regulate myeloid cell di¡erentia-
tion through their di¡erential e¡ects on the c-fos gene tran-
scription.
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